This article originally appeared on Business Wire, December 19, 2013.
CAMBELL, Calif.–(BUSINESS WIRE)–
Preliminary clinical study results from a randomized, controlled, prospective clinical study comparing the ZipLine Surgical Skin Closure to traditional stitches for skin cancer excision were presented at the 16th Annual Mount Sinai Winter Symposium on Advances in Medical and Surgical Dermatology, which took place Dec. 6-8, 2013, in New York.
Hooman Khorasani, M.D., Chief of the Division of Mohs, Reconstructive and Cosmetic Surgery at Mount Sinai School of Medicine and principal investigator for the study, presented the preliminary results to an audience of over 400 dermatological surgeons. He is deeply involved in minimal scar wound repair research and has done extensive research in this area of scar-less wound healing. He is currently conducting two clinical trials addressing improved scarring after surgery.
“In the study, the ZipLine device produced similar cosmetic outcomes to a traditional suture closure while significantly reducing the treatment time, which can in turn reduce the overall cost of the procedure. In addition, since with the ZipLine there are no sutures to remove, this limited the need for immediate patient return, which can benefit both the patient and clinic. The patient can instead return later when the wound is more healed,” said Dr. Khorasani. The preliminary data suggested a 57% reduction in wound closure procedure time when using the ZipLine device instead of sutures. The final study results will be submitted for publication in a peer-reviewed dermatological surgery journal.
The ZipLine device attaches to the skin around a wound using pressure-sensitive adhesive, and does not pierce the skin like sutures and staples. This eliminates the pathways through the skin that can cause surgical site infections. When adequate healing has taken place, the ZipLine device is gently peeled from the skin as with tape.
“We are pleased to see these outcomes from Dr. Khorasani’s study, as they further validate the speed advantage of the ZipLine devices while providing excellent cosmesis,” said John Tighe, President and CEO of ZipLine Medical, Inc.
ZipLine Medical (www.ziplinemedical.com), headquartered in Campbell, Calif., is an emerging medical device company developing cost-effective, noninvasive surgical skin closure devices for suture-like outcomes at the speed of staples, with a reduced risk of surgical site infection. Because skin-closure is the common denominator of nearly all surgical procedures, Zip™ Surgical Skin Closure devices have extensive applicability across multiple medical specialties. The Company’s addressable market opportunity is estimated at $4 billion worldwide. Zip™ Surgical Skin Closure devices are classified by the U.S. FDA as ‘Class I, Exempt.’
ZipLine, Zip and PRELOC are trademarks of ZipLine Medical, Inc.
Media Contact for ZipLine Medical:
Ronald Trahan, APR, 508-359-4005, x108
rctrahan@ronaldtrahan.com
Investor Contact for ZipLine Medical:
Lori Munoz, 408-684-0752
lmunoz@ziplinemedical.com